Sonnet BioTherapeutics shares are trading higher after the company entered into a clinical collaboration agreement with the Sarcoma Oncology Center to commence a Phase 1/2a study of SON-1210 in combination with chemotherapy for the treatment of pancreatic cancer.
Portfolio Pulse from Benzinga Newsdesk
Sonnet BioTherapeutics shares rise following a clinical collaboration agreement with the Sarcoma Oncology Center to start a Phase 1/2a study of SON-1210 with chemotherapy for pancreatic cancer treatment.
August 19, 2024 | 12:51 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sonnet BioTherapeutics' stock is up due to a new clinical collaboration with the Sarcoma Oncology Center for a Phase 1/2a study of SON-1210 in pancreatic cancer treatment.
The announcement of a clinical collaboration for a new study is a positive development for Sonnet BioTherapeutics, indicating progress in their drug pipeline and potential future revenue from successful trials. This news is likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100